What is your approach to curative-intent therapy for a young, fit patient with newly-diagnosed monomorphic epitheliotropic intestinal T cell lymphoma (MEITL)?

If >= 10% of the cells express CD30 by IHC, I would treat with BV+CHP x 6 cycles rather than CHOP according to the ECHELON-2 trial (although this trial included only 3 patients with EATL). Historically, the 5-year OS rate with anthracycline-based chemotherapy alone is approximately 10 to 20%, so for...